The large body of clinical experience associated with lipid emulsion therapy for severe cardiovascular and central nervous system toxicity has generated a great deal of pre-clinical investigation aimed at a better understanding of lipid emulsion activity and more formal, controlled evaluation of effectiveness that cannot be obtained from clinical series and individual case reports. In this issue of AYMHM, four recent lipid emulsion studies are reviewed.
Introduction:
The large body of clinical experience associated with lipid emulsion therapy for severe cardiovascular and central nervous system toxicity has generated a great deal of pre-clinical investigation aimed at a better understanding of lipid emulsion activity and more formal, controlled evaluation of effectiveness that cannot be obtained from clinical series and individual case reports. In this issue of AYMHM, four recent lipid emulsion studies are reviewed.
Article Title: Fettiplace MR, Kowal K, Ripper R, Young A, Lis K, Rubinstein I, Bonini M, Minshall R, Weinberg G. Insulin signaling in bupivacaine-induced cardiac toxicity: sensitization during recovery and potentiation by lipid emulsion. Anesthesiol. 2016; 124:428-42 . Background: The mechanism for reversal of toxicity with intravenous lipid emulsion (ILE) is not well understood. Current theories include a scavenging effect (Blipid sink^) and a direct effect leading to increased cardiac output. However, the full extent of the cellular signaling responsible for this direct effect is unknown. Research Question: Does bupivacaine disrupt the insulin signaling pathway in vivo? Does ILE modify bupivacaine's effect on this pathway? Methods: Sprague-Dawley rats were used in both in vivo and ex vivo models of bupivacaine toxicity. In vivo model: 29 rodents were divided into the following four groups: bupivacaine (10 mg/kg); bupivacaine + ILE (10 ml/kg, 30 %*); bupivacaine + pretreatment with Wortmannin (an irreversible Pi3k inhibitor, 25 mcg/kg); or ILE (10 ml/kg, 30 %) alone. The bupivacaine dose was less than IC50 for cardiac sodium channel toxicity. Animals were sacrificed using rapid cardiac excision at 1.5, 5, and 10 min. Ex vivo model: 20 isolated rat hearts were suspended from a Langendorff apparatus with cannulation at the aortic root. Hearts were treated with one of the following: 500 μM bupivacaine over 30 s; 500 μM of bupivacaine + pretreatment with 50 μM of LY294002 (a reversible Pi3k inhibitor); or ILE (10 ml/kg, 20 %) alone. Hearts were flash frozen 2 min after completion of the infusion. The apex of the hearts and apical pole of the right kidney (in vivo model) were assayed for multiple insulin signaling enzymes using Western blot with attempted control for equal loading. Glycogen stores were assessed using a colorimetric assay. [*The primary investigator confirms that units for ILE were inconsistently reported in the manuscript and that the correct units are ml/kg.] Results: In the absence of toxicity, insulin signaling causes an increased phosphorylation of protein kinase B (Akt), a protein involved in contractility, and a decreased phosphorylation of 5′-adenosine monophosphate-activated protein kinase (AMPK), a protein that modulates downstream activity of Akt. These two pathways converge at tuberous sclerosis 2 (TSC2). Toxicity from bupivacaine inhibited the insulin signaling pathway through two mechanisms: (1) dephosphorylation Akt and (2) phosphorylation of AMPK. This effect is presumably the cause of decreased contractility independent of sodium channel blockade. A partial effect on downstream enzymes may be due to the countervailing force at TSC2 from bupivacaine's effect to increase phosphorylation of AMPK. Akt activity was also blunted in the kidney with a decrease in phosphorylation. Toxicity was exacerbated with the use of Wortmannin but pretreatment with LY294002 significantly delayed the time to asystole. These irreversible and reversible inhibitors act on the phosphorylation pathway at the step preceding Akt.
During recovery from toxicity, hyperphosphorylation at Akt and throughout the downstream enzymes was observed, possibly due to a lack of feedback control during toxicity. Wortmannin blunted enzyme phosphorylation and cardiac recovery by blocking upstream to Akt, but LY294002 did not significantly alter recovery (with the same site of action).
Treatment with ILE decreased the time to physiologic recovery (within 5 versus 10 min) and increased phosphorylation of Akt without a change on enzymes past TSC2. Enzymes in both treatment groups were hyperphosphorylated at 10 min. ILE did not affect the increase in phosphorylation of AMPK which may have contributed to a lack of effect at the downstream enzymes.
Conclusion:
The results of this study support findings from previous in vitro studies that bupivacaine caused dephosphorylation of Akt but phosphorylation of AMPK. ILE increases phosphorylation of Akt independently and following bupivacaine toxicity, but does not affect AMPK. Loss of a feedback signal during toxicity may sensitize the insulinergic pathway leading to an increase in glycogen stores by 40 % (reported in discussion section). Study authors theorized that the clinical implications of their findings may include refinement of when to utilize ILE for drug toxicity, targeting drugs that interfere with insulin signaling. The authors conclude ILE would have greatest effect on those toxins affecting the Akt signaling pathway or causing a decrease in insulin receptor sensitivity (i.e., calcium channel antagonists and cyclic antidepressants). Critique: The investigators chose a dose of bupivacaine that resulted in brief, survivable asystole, but without the confounding effect of sodium channel antagonism. No untreated controls were performed for comparison of effect of the procedure on insulin signaling. Also, the ex vivo protocol included a group that received no experimental drugs but the results were not included. Some methodology details were difficult to discern. The number of rodents separated into each treatment arm of the in vivo protocol and decision for separation (i.e., randomization) was not defined. Baseline characteristics of rodents were not included limiting review of inter-and intragroup variability. The dose of ILE appears to vary between groups for an undisclosed reason: the bupivacaine + ILE group received 10 mg/kg of 30 % ILE; the ILE alone group received 10 mL/kg (presumably 30 % ILE); and the ex vivo ILE alone group received 10 ml/kg of 20 % ILE. Without changes in enzyme activity downstream from TSC2, the effect of phosphorylation of Akt by ILE remains unclear. Implication for Toxicologists: Though ILE's mechanism for treating drug toxicity is likely multifactorial, this research provides evidence for an additional cellular mechanism. Further investigations into the insulin signaling pathway may provide a better understanding of which toxins are most amenable to ILE therapy as well as better insight into other synergistic treatments.
Article Title: Fulton LV, Fabich RA, Bhatta J, Fletcher B, Leininger K, Lienesch K, Rodriguez TA, Coyner JL, Johnson AD, O'Sullivan J. Comparison of resuscitative protocols for bupropion overdose using lipid emulsion in a swine model. Mil Med. 2016; 181:482-487 . Background: Bupropion is a highly lipophilic atypical antidepressant that can cause fatal cardiac toxicity. However, research on the use and efficacy of advanced cardiac life support (ACLS) and intravenous lipid emulsion (ILE) in resuscitation of bupropion toxicity is limited and the optimal resuscitation is not fully defined. Research Question: Will the addition of ILE to standard ACLS interventions (epinephrine, vasopressin) improve survival following bupropion toxicity in a porcine model? Methods: Swine were sedated, anesthetized, intubated, mechanically ventilated, and instrumented for drug delivery and cardiovascular monitoring. They were allowed to stabilize after surgery and then infused with 35 mg/kg bupropion that resulted in cardiac arrest (defined as a non-perfusing rhythm).
Once a non-perfusing rhythm was confirmed, mechanical cardiopulmonary resuscitation (CPR) was performed and defibrillation was used for any shockable rhythm. Animals were randomized into eight experimental treatment groups (n = 7 each group): controls (CPR only, no medication); epinephrine alone; vasopressin alone; ILE alone; epinephrine + vasopressin; epinephrine + ILE; vasopressin + ILE; or epinephrine + vasopressin + ILE. The treatments w ere i nitiated after 2 m in of CPR. Hemodynamic, respiratory, and EKG monitoring were performed for 30 min after initiating treatments. The primary outcomes were survival and time to return of spontaneous circulation (ROSC). Results: No swine survived in the control and lipid only groups. Swine that were given epinephrine, alone or in combination with other drugs, had a significant increase in survival rate when compared to other options (OR 22, 95 % CI 5.47-88.43). 6/7 animals survived when treated with epinephrine alone, epinephrine + vasopressin, or epinephrine + vasopressin + ILE. Within the epinephrine + ILE group, 4/7 animals survived. Vasopressin alone or combined with ILE did not improve survival (2/7). The epinephrine + ILE group had the quickest time to ROSC: 7 min (p < 0.02 via Cox regression). Conclusion: The investigators concluded that epinephrine should be the primary treatment for severe bupropion toxicity and that ILE has a role as an adjunct to epinephrine.
Critique: Multiple sedation and anesthetic agents with direct cardiovascular effects were used. Details were missing from the methods. The exact formulation or dose of ILE was not provided. It is unclear if the total volume of fluids administered during resuscitation was similar between treatment groups. The order of drug administration for the combination treatment groups was not described. Details were also missing from the results. Multiple cardiovascular and pulmonary measures were performed throughout the study, but only mean arterial pressure was included. There was no report of which treatment groups, if any, required cardioversion or defibrillation. The actual amount of epinephrine given in each treatment group was not reported and would be interesting to compare between the different groups. It would be especially interesting to compare epinephrine requirements between the epinephrine alone vs epinephrine + ILE groups as prior work (Carreiro et al. J Med Toxicol. 2013; 9:220-225) suggests that ILE alters responsiveness to epinephrine. The current study results suggest such an interaction occurred: epinephrine + ILE provided the most rapid time to ROSC, but epinephrine treatment alone may have higher survival than epinephrine + ILE (6/7 vs 4/7). Thus, the conclusion that acute bupropion toxicity would be improved by the use of CPR with epinephrine and ILE must be tempered by a possible interaction between the different treatments. Lastly, the authors include an interesting, well-referenced discussion on the mechanism of bupropion cardiotoxicity and the validity of the swine model for ILE investigations. Implication for Toxicologists: Noting the limitations, it appears that epinephrine is critical in resuscitation of bupropion-induced cardiac arrest, and that ILE may play an adjunctive role.
Article Title: Chai PR, Hack JB. Intravenous lipid emulsion in the resuscitation of cocaine-induced cardiovascular arrest in the rat model. Am J Emerg Med. http://dx.doi.org/10.1016/j. ajem.2016.01.026 Background: Cocaine is a lipophilic molecule with direct cardiotoxicity that can result in dysrhythmias, cardiac arrest, and death. Intravenous lipid emulsion (ILE) is an emerging treatment with observed benefit in select, lipid soluble cardiotoxic drugs. Prior work by the authors showed that ILE pre-treatment diminished cocaine toxicity. Research Question: Will ILE therapy restore circulation in rats following cardiovascular collapse from acute intravenous cocaine toxicity? Methods: Twelve male Sprague-Dawley rats with indwelling femoral arterial and venous catheters were anesthetized with inhaled isoflurane. The animals were divided into high-and low-dose cocaine groups: group A (n = 7) received 10 mg/kg and group B (n = 5) received 5 mg/kg, each dose over 30 s. Animals were observed until cardiac arrest (i.e., asystole) occurred. Chest compressions were then performed via handpowered compression device at a rate of 200 beats per minute and rats received either ILE 15 ml/kg* 20 % ILE IV (group A, n = 6; group B, n = 3) or normal saline (NS) 15 ml/kg IV (group A, n = 1; group B, n = 2). Animals were monitored for a total of 15 min with 5-s interruptions every minute to check for organized cardiac activity or arterial pulse wave. Data was presented via descriptive statistics with 95 % confidence intervals. [*The authors confirm the units for the lipid emulsion dose was incorrectly published as mg/kg.] Results: Vital signs were similar among rats prior to the start of the trial with an average heart rate of 344 bpm (95 % CI, 329-359). All 12 rats sustained cardiac arrest after an average of 4.42 s (95 % CI, 0.80-2.87) following cocaine administration. One rat in the high-dose cocaine group responded to ILE with a return of spontaneous circulation after 11 min. No other ILE or NS rats survived and there was no statistical significance between groups. Conclusion: A treatment effect was not observed in this ILE rescue model of cocaine-induced cardiac arrest. Critique: The authors acknowledge several important limitations, including a small number of control animals (to avoid unnecessary suffering), use of passive ventilation, and lack of monitoring metabolic and ventilatory parameters. There were also a small number of ILE-treated animals which may have resulted in underpowering of the study to detect a treatment effect. The respiratory and cardiovascular effects of isoflurane anesthesia may have influenced the results along with differences in rat physiology that therefore make extrapolation to humans challenging. Implications for Toxicologists: Due to the limitations of this study, we are unable to determine the effectiveness of ILE therapy on cocaine-induced cardiac arrest. More research is needed to explore the value of ILE for cocaine resuscitation.
Article Title: Tulgar S, Kose HC, Piroglu ID, Karakilic E, Ates NG, Demir A, Gergerli R, Guven S, Piroglu MD. Comparison of effects of separate and combined sugammadex and lipid emulsion administration on hemodynamic parameters and survival in a rat model of verapamil toxicity. Med Sci Monit. 2016; 22:984-990 . Background: Calcium channel antagonist toxicity remains a challenge to treat. Intravenous lipid emulsion (ILE) therapy may be beneficial but its value is not fully elucidated. Cyclodextrins (e.g., sugammadex) are an emerging experimental treatment based on the ability to bind verapamil. Research Question: How will the administration of ILE and sugammadex (S), alone and combined, affect hemodynamic measures and survival in a rodent model of severe verapamil toxicity? Methods: Sprague-Dawley rats were anesthetized with ketamine, instrumented, allowed to stabilize, and then intoxicated with a continuous verapamil infusion. Five minutes after starting verapamil, experimental groups received equal volumes of either saline (controls), ILE; S; or ILE + S. Animals were monitored until death. Survival (primary outcome), time to death, mean arterial pressure (MAP), and heart rate (secondary outcomes) were analyzed. Results: Verapamil infusion consistently produced bradycardia, hypotension, and death in all control animals (median time to death 19 min and lethal dose 12 mg/kg). Both experimental treatments increased survival; survival time (S 37 min; ILE 30 min; and ILE + S 37 min), and lethal dose of verapamil (S 23 mg/kg; ILE 19 mg/kg; and ILE + S 23 mg/kg) compared with controls. Both S and ILE + S treatments increased heart rate at the end of verapamil infusion (S 277 bpm and ILE + S 225 bpm vs controls 173 bpm). From the end of verapamil infusion until the end of the experiment, combined ILE + S therapy increased heart rate and MAP. Conclusion: Administration of either sugammadex or ILE delayed verapamil toxicity and increased survival in a rodent model. Combined therapy may lessen vasopressor requirement.
Critique: Overall, this is a well-designed comparative rodent model of severe verapamil toxicity. It contains a few noteworthy limitations. The use of ketamine anesthesia may have affected hemodynamic parameters. Because experimental treatments began 5 min after verapamil was started, but before developing toxicity, the design is functionally a pre-treatment rather than rescue study. Equalizing experimental treatment volume makes the dose of ILE difficult to determine in the combined treatment group. The reported results for heart rate and MAP between completion of verapamil infusion and end of the experiment were not supported by statistical analysis. The authors cannot speculate on vasopressor support as the protocol did not address this aspect of clinical care. Implication for Toxicologists: This study adds to our growing body of knowledge regarding resuscitation of calcium channel antagonist toxicity. Further work is required to better understand the role that ILE and sugammadex may play in these poisonings.
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